POC °¨¿°Áõ °Ë»ç ½ÃÀå : Áúº´ À¯Çüº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
PoC Infectious Disease Testing Market, By Disease Type, By Technology, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1575021
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 322 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,651,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,655,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,086,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

2023³â POC °¨¿°Áõ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2023³â 114¾ï 9,832¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö CAGR 4.40%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

POC °¨¿°Áõ °Ë»ç ½ÃÀå - ½ÃÀå ¿ªÇÐ

°¨¿°º´ È®»ê°ú ½Å¼ÓÇÑ Áø´ÜÀÇ Çʿ伺 Áõ°¡, µðÁöÅÐÈ­°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»ó

COVID-19, µ¶°¨, HIV, °áÇÙ, ¼ºº´ µî °¨¿°¼º ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, PCR°ú °°Àº ºÐÀÚÁø´Ü, ¸é¿ªºÐ¼®, ¹Ì¼¼ À¯Ã¼ µî °Ë»ç ±â¼úÀÇ Çõ½ÅÀ¸·Î POCT ÀåºñÀÇ ¹Î°¨µµ, ƯÀ̼º, »ç¿ë ÆíÀǼºÀÌ Çâ»óµÇ¾î POCT Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. POCT ÀåºñÀÇ ¹Î°¨µµ, ƯÀ̼º, »ç¿ë ÆíÀǼºÀÌ Çâ»óµÇ¾î POC °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¶±â Áø´Ü°ú Á¤±âÀûÀÎ °ËÁøÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, POCT´Â Àü¹® °Ë»ç ½Ã¼³°ú ÀηÂÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ Àüü °Ë»ç ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖÀ¸¸ç, POCT ±â±â¸¦ µðÁöÅÐ °Ç°­ Ç÷§Æû ¹× ÀüÀÚ ÀÇ·á ±â·Ï(EMR)°ú ÅëÇÕÇÏ¿© ¿øÈ°ÇÑ µ¥ÀÌÅÍ °øÀ¯, ¿ø°Ý ¸ð´ÏÅ͸µ ¹× Áúº´ °ü¸®¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÅÈï±¹Àº ÀÇ·á ÀÎÇÁ¶ó¿Í ¼÷·ÃµÈ Àη ºÎÁ·À» ÇØ°áÇϱâ À§ÇØ POCT ¼Ö·ç¼ÇÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. Ä¿³ØÆ¼ºñƼ ±â´ÉÀ» ÅëÇØ Áúº´ ¹ß»ýÀ» ÃßÀûÇÏ°í ¿ªÇÐ °¨½Ã¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡Àº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

POC °¨¿°Áõ °Ë»ç ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 4.40%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áúº´ À¯Çüº°·Î º¸¸é 2023³â¿¡´Â ½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä·Î ÀÎÇØ COVID-19 ÁúȯÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

±â¼úº°·Î´Â ºÐÀÚ °Ë»çÀÇ ¹ßÀüÀ¸·Î 2023³â ºÐÀÚÁø´Ü¾à ºÎ¹®ÀÌ ÁÖ¿ä ±â¼ú ºÎ¹®À¸·Î ºÎ»óÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â POC Áø´Ü ¿¬±¸¼Ò ¹× ¼¾ÅÍ µîÀÇ Áõ°¡·Î ÀÎÇØ 2023³â ÃÖÁ¾»ç¿ëÀÚ Áß Áø·á¼Ò°¡ °¡Àå ¸¹Àº ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

Áö¿ªº°·Î º¸¸é ºÏ¹Ì´Â ÷´Ü ÇコÄÉ¾î ±â¼ú°ú ÀÎÇÁ¶ó°¡ Á¸ÀçÇϱ⠶§¹®¿¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

POC °¨¿°Áõ °Ë»ç ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è POC °¨¿°Áõ °Ë»ç ½ÃÀåÀº Áúº´ À¯Çü, ±â¼ú, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Áúº´ À¯Çü¿¡ µû¶ó HIV, µ¶°¨, °áÇÙ ¹× ¾à¹° ³»¼º POC, HBV POC, HPV POC, COVID-19 Áúº´, ±âŸ µî 7°¡Áö ¹üÁÖ·Î ³ª´µ¸ç, COVID-19 Áúº´ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼ö¿ä Áõ°¡°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ±â¼ú¿¡ µû¶ó Ãø¸é È帧 ¸é¿ªÃøÁ¤¹ý, ÀÀÁý °Ë»ç, ºÐÀÚÁø´Ü¹ý, ±âŸ µî 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº ºÐÀÚÁø´Ü ºÐ¾ßÀÔ´Ï´Ù. ºÐÀÚ °Ë»ç´Â Á¤È®µµ°¡ ³ô°í À¯ÀüÀÚ Àç·á 󸮿¡ ÀûÇÕÇϱ⠶§¹®¿¡ ÀÌ ºÐ¾ßÀÇ ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó º´¿ø, Ŭ¸®´Ð, ÀçÅÃÀÇ·á, ±âŸ µî 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. Ŭ¸®´Ð ½ÃÀåÀÌ ½ÃÀåÀ» Áö¹èÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, POC °¨¿°¿¡ ´ëÇÑ ½Å¼ÓÇÑ Ä¡·á¸¦ Á¦°øÇÏ´Â ÀÓ»ó ¼¾ÅÍÀÇ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

POC °¨¿°Áõ °Ë»ç ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ °ÉÃÄ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ºÏ¹Ì, ƯÈ÷ ¹Ì±¹Àº ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº Áúº´ ºÎ´ã, ½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ³ôÀº °ü½ÉÀ¸·Î ÀÎÇØ Àü ¼¼°è POCT ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸°¡ ¸¹°í, Àü¿°º´ À¯ÇàÀÌ Áõ°¡Çϰí, Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ƯÈ÷ ³óÃÌ ¹× ¿Üµý Áö¿ª¿¡¼­ ÁýÁßÀûÀÎ °Ë»ç ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º ºÎÁ·À» ÇØ°áÇϱâ À§ÇØ POCTÀÇ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

POC °¨¿°Áõ °Ë»ç ½ÃÀå - °æÀï »óȲ:

POC °¨¿°Áõ °Ë»ç ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ°í ¼ö¸¹Àº ¼¼°è ¹× Áö¿ª ±â¾÷ÀÌ Á¸ÀçÇÏ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. °¢ ±â¾÷µéÀº Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ °ü¸® ¹× ¿ø°Ý ¸ð´ÏÅ͸µ°ú °°Àº µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀ» POCT Á¦Ç°¿¡ ÅëÇÕÇϱâ À§ÇØ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾÷üµéÀº CRISPR ±â¹Ý Áø´Ü¾à°ú ÀÚµ¿ µðÁöÅÐ ÆÇµ¶±â µî Â÷¼¼´ë ±â¼úÀ» ÅëÇØ POCT ±â±âÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ¸¦ Çâ»ó½ÃŰ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

2024³â 1¿ù, ·Î½´´Â ·ç¹Ì¶óµ¦½ºÀÇ POCT ±â¼ú Àμö¸¦ ¿Ï·áÇß½À´Ï´Ù. ·ç¹Ì¶óµ¦½ºÀÇ Ç÷§Æû¿¡´Â ÀÏ·ÃÀÇ ¸é¿ªÃøÁ¤ ¹× ÀÓ»ó È­ÇÐ °Ë»ç°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

2023³â 2¿ù, ½á¸ðÇǼŠ»çÀ̾ðƼÇÈÀº ¸¶ÀÌ·¦°ú Á¦ÈÞÇÏ¿© Àεµ¿¡¼­ °¨¿°¼º Áúȯ¿ë RTPCR ŰƮ¸¦ Ãâ½ÃÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå POC °¨¿°Áõ °Ë»çÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå POC °¨¿°Áõ °Ë»ç ¾÷°è Á¶»ç

Á¦5Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå »óȲ

Á¦7Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå - Áúȯ À¯Çüº°

Á¦8Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå - ±â¼úº°

Á¦9Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå POC °¨¿°Áõ °Ë»ç ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - POC °¨¿°Áõ °Ë»ç ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

PoC Infectious Disease Testing Market size was valued at USD 11,498.32 Million in 2023, expanding at a CAGR of 4.40% from 2024 to 2032.

Point of Care Infectious Disease Testing (POCT) refers to diagnostic tests conducted at or near the site of patient care, such as in a clinic, doctor's office, or at home. These tests are designed to detect infectious diseases quickly, providing results within minutes to a few hours. This enables healthcare providers to make immediate decisions about treatment and management, reducing the need for additional lab testing and follow-up visits.

PoC Infectious Disease Testing Market- Market Dynamics

Increasing prevalence of infectious diseases and need for rapid diagnostics along with digitization is expected to propel market demand

The increasing incidence of infectious diseases like COVID-19, influenza, HIV, tuberculosis, and sexually transmitted infections has heightened the demand for rapid and reliable diagnostics. Innovations in testing technologies, including molecular diagnostics like PCR, immunoassays, and microfluidics, have improved the sensitivity, specificity, and ease of use of POCT devices, boosting demand for POC testing. Public awareness regarding the benefits of early diagnosis and regular screening is also rising, contributing to market growth.

Further, POCT reduces the overall cost of testing by eliminating the need for specialized lab facilities and personnel. Integration of POCT devices with digital health platforms and electronic medical records (EMRs) allows for seamless data sharing, remote monitoring, and improved disease management. Emerging economies are adopting POCT solutions to address the shortage of healthcare infrastructure and skilled personnel. Connectivity features enable better tracking of disease outbreaks and epidemiological surveillance. These benefits are expected to bolster market growth.

PoC Infectious Disease Testing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.40% over the forecast period (2024-2032)

Based on Disease Type segmentation, the COVID-19 disease segment was predicted to show maximum market share in the year 2023, owing to high need for fast diagnostics.

Based on Technology segmentation, molecular diagnostics segment was the leading Technology segment in 2023, due to the developments in molecular testing.

Based on End User segmentation, clinics segment was the leading End User segment in 2023, due to increasing number of POC diagnostics labs, centers, etc.

On the basis of region, North America was the leading revenue generator in 2023, due to the presence of advanced healthcare technology and infrastructure.

PoC Infectious Disease Testing Market- Segmentation Analysis:

Global PoC Infectious Disease Testing Market is segmented on the basis of Disease Type, Technology, End User, and Region.

The market is divided into seven categories based on Disease Type: HIV, influenza, TB & drug resistant POC, HBV POC, HPV POC, COVID-19 disease, and others. The COVID-19 disease segment dominates the market. The increasing demand from PCR testing for COVID-19 has boosted segment growth.

The market is divided into four categories based on Technology: lateral flow immunoassay, agglutination test, molecular diagnostics, and others. The molecular diagnostics segment dominates the market. The molecular tests are accurate and preferred in genetic material processing which is accelerating segment demand.

The market is divided into four categories based on End User: hospitals, clinics, homecare, and others. The clinics segment dominates the market and is expected to maintain its high dominance during the forecast period. The rising number of clinical centers providing rapid treatment in POC infectious diseases is boosting market growth.

PoC Infectious Disease Testing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, particularly the United States, holds the largest share of the global POCT market due to its advanced healthcare infrastructure, high disease burden, and strong emphasis on rapid diagnostics. The Asia-Pacific region is expected to witness the highest growth rate due to the large population base, rising prevalence of infectious diseases, and growing awareness about early diagnosis. The adoption of POCT is particularly high in rural and remote areas to address the lack of access to centralized laboratory facilities.

PoC Infectious Disease Testing Market- Competitive Landscape:

The PoC Infectious Disease Testing market is highly competitive and characterized by the presence of numerous global and regional players. Companies are increasingly investing in integrating digital health solutions, such as cloud-based data management and remote monitoring, into their POCT products. In addition, companies are focusing on enhancing the sensitivity and specificity of their POCT devices through next-generation technologies, such as CRISPR-based diagnostics, and automated digital readers.

In January 2024, Roche completed acquisition of LumiraDx's point of care technology. The LumiraDx's platform includes a series of immunoassay and clinical chemical tests.

In February 2023, Thermo Fisher Scientific partnered with Mylab to introduce RTPCR kits for infectious disease in India.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL POC INFECTIOUS DISEASE TESTING MARKET KEY PLAYERS

GLOBAL POC INFECTIOUS DISEASE TESTING MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL POC INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019-2032

GLOBAL POC INFECTIOUS DISEASE TESTING MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL POC INFECTIOUS DISEASE TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. PoC Infectious Disease Testing Market Overview

2. Executive Summary

3. PoC Infectious Disease Testing Key Market Trends

4. PoC Infectious Disease Testing Industry Study

5. PoC Infectious Disease Testing Market: COVID-19 Impact Analysis

6. PoC Infectious Disease Testing Market Landscape

7. PoC Infectious Disease Testing Market - By Disease Type

8. PoC Infectious Disease Testing Market - By Technology

9. PoC Infectious Disease Testing Market - By End User

10. PoC Infectious Disease Testing Market- By Geography

11. Key Vendor Analysis- PoC Infectious Disease Testing Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â